PRIMARY

EFFECTIVENESS ENDPOINT:

Procedure such defined as ≤50% residual stenosis for all treated lesions without significant angiographic complications

DISRUPT BTK II

By The Numbers

250
Patients
40
Global sites
Lesion lengths up to 200mm
Outcomes out to 2 Years

DISRUPT BKT II
STUDY LEADERSHIP

Venita Chandra MD
Clinical Associate Professor of Surgery
Associate Program Director - Vascular Surgery
Medical Director - Stanford Advanced Wound Center

DISRUPT BKT II
TRIAL DESIGN SIGNIFICANCE

Studies a real-world CLI patient population, including patients with long, calcified lesions.

Prospective, multi-center, core lab adjudicated.

Moderate-severe calcium assessed by angiography or IVUS.

IVL is the definitive treatment.

Secondary Endpoints: Primary Patency, Clinically Relevant TLF, ABI/TBI & RC, QoL, Wound Healing.

Ready to Make Waves with Shockwave IVL?

ico email Connect